Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

With an eye towards an IND
March 2020
SHARING OPTIONS:

CAMBRIDGE, Mass.—Kintai Therapeutics, a Flagship Pioneering company, has advanced KTX-0200 into IND-enabling studies after the anti-obesity agent demonstrated efficacy in preclinical studies. KTX-0200 resulted in sustained weight loss of 14 percent in chronic diet-induced obesity rodent models, as well as a 12-percent improvement in oral glucose clearance (per an oral glucose tolerance test) and a 14.5-percent improvement in insulin sensitivity (based on glucose clearance in an insulin tolerance test). The compound also demonstrated significant improvements in liver health in animal models; in the Gubra NASH model, KTX-0200 treatment led to a 30-percent reduction in liver fat, a 19-percent decrease in total liver weight and a 38-percent decrease in liver transaminases known to be indicative of liver damage. KTX-0200 is a novel, oral, small-molecule agent, and has been shown to lead to weight loss with little change in eating habits.
 
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.